Therapy Areas: Oncology
Alpha Tau Medical treats first patient in feasibility study assessing Alpha DaRT in patients with prostate cancer
23 June 2022 -

Alpha Tau Medical Ltd. (Nasdaq: DRTS), an Israel-based company that develops alpha-radiation cancer therapy Alpha DaRT, announced on Wednesday that it has treated the first patient in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer at the Rambam Health Care Center in Haifa, Israel.

The primary objectives of this study are to assess the feasibility and safety of intratumoral Alpha DaRT source implantation for the treatment of local prostate cancer prior to surgery. Secondary objectives include assessing radiological and pathological objective response rate of the tumour, and changes in quality-of-life measures. The study involves two separate procedures, with surgical resection of the prostate 50 days following Alpha DaRT source insertion, and can recruit up to 10 patients. The surgical resection will be performed at the Carmel Medical Center in Haifa, Israel using a da Vinci surgical robot, and will be led by Dr Yuval Freifeld and his senior team.

Alpha Tau CEO Uzi Sofer, said, 'This is a historic day for Alpha Tau. After gaining a wealth of experience in treating superficial cancers such as those of the skin, head & neck, and breast, we are thrilled to have treated the first prostate patient, our first internal organ treatment. Our pre-clinical data show that the Alpha DaRT technology may have potential to address a very broad range of solid tumour types, and our strategy is to expand our clinical studies across multiple tumour types in order to evaluate the full potential of the Alpha DaRT. This study suggests our ability to deliver this promising treatment beyond superficial tumours and is an important milestone in executing on this strategy.'